Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
PhRMA Chief Warns Japan Is Losing Its Appeal, Urges End to On-Patent Price Cuts
Japan’s continued drug price reductions are diminishing the country’s attractiveness as a market for innovative medicines, said Albert Bourla, chair of the Pharmaceutical Research and Manufacturers of America (PhRMA), on November 18. Speaking at a press conference during his visit…
To read the full story
Related Article
ORGANIZATION
- Ease Foreign Price Adjustment Rules for New Drugs to Counter MFN Policy: FPMAJ
June 15, 2026
- Raise Foreign Price Adjustment Cap for Listed Products in German Cases: FPMAJ
June 15, 2026
- FPMAJ Seeks Predictability in Price Maintenance System for Innovative Medicines
June 15, 2026
- LLP Extra Patient Charge Influences Generic Adoption at Over 40% of Hospitals: FPMAJ
June 15, 2026
- Society Envisions 1 Trillion Yen in Overseas Sales for Japan’s Off-Patent Drug Sector by 2040
June 9, 2026
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…